Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases. It is currently studying TDI01, a highly selective, potent inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States.

Graviton Bioscience is a company based out of New York, New York, United States.

Graviton Bioscience

A warm welcome to Enavate Sciences as they join our current investors, marking a significant step forward to advance our ROCK2 inhibitors pipeline

https://lnkd.in/etXG3Urs

Graviton's CEO Dr. Samuel D. Waksal, Ph.D., is scheduled to deliver a keynote speech at the 20th BayHelix Annual Conference this Saturday, January 6, at 13.05 PST at the Grand Hyatt at SFO.

Excited to announce our latest news
https://lnkd.in/e8Cnhxut

COM:GRAVITONCORP

Graviton Bioscience Corporation

Analysis Not Available